Literature DB >> 23568001

Long-term risk perceptions of women with ductal carcinoma in situ.

Kathryn J Ruddy1, Meghan E Meyer, Anita Giobbie-Hurder, Karen M Emmons, Jane C Weeks, Eric P Winer, Ann H Partridge.   

Abstract

INTRODUCTION: Previous research has demonstrated that many women with ductal carcinoma in situ (DCIS) overestimate their risk for future breast cancer at the time of diagnosis and soon thereafter. This study aims to evaluate risk perceptions after 5 years. PATIENTS AND METHODS: In a longitudinal cohort study, we mailed long-term follow-up surveys to 315 women who had previously responded to a survey 18 months after they were diagnosed with DCIS, excluding those who had experienced recurrence and those not treated at our institution. We evaluated risk perceptions with items used previously in the cohort.
RESULTS: One hundred ninety-three women (61%) responded. The median time since diagnosis was 5.9 years. We excluded 12 because of recurrence. Of the 181 remaining, 32% perceived at least a moderate 5-year risk for developing DCIS again, 43% perceived at least a moderate lifetime risk for developing DCIS again, 27% perceived at least a moderate 5-year risk for invasive breast cancer, 38% perceived at least a moderate lifetime risk for invasive breast cancer, and 24% perceived at least a moderate risk for DCIS spreading to other body parts. In a multivariate model, worse financial status and higher perceived risk in the previous survey were the only predictors of at least a moderate perception of risk for DCIS spreading.
CONCLUSION: Women with a history of DCIS continue to harbor inaccurate perceptions of their risk for future breast cancer events even 5 years after diagnosis.

Entities:  

Mesh:

Year:  2013        PMID: 23568001      PMCID: PMC3639521          DOI: 10.1634/theoncologist.2012-0376

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  18 in total

1.  Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification.

Authors:  Fattaneh A Tavassoli
Journal:  Nat Clin Pract Oncol       Date:  2005-03

2.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

Authors:  B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy.

Authors:  L L Kestin; N S Goldstein; M D Lacerna; M Balasubramaniam; A A Martinez; M Rebner; J Pettinga; R C Frazier; F A Vicini
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

4.  Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast.

Authors:  Adele A Bailes; Henry M Kuerer; Sara A Lari; Lovell A Jones; Abenaa M Brewster
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

5.  The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.

Authors:  Melinda E Sanders; Peggy A Schuyler; William D Dupont; David L Page
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

6.  Ductal carcinoma in situ of the breast--a review of diagnosis, treatment and outcome in a hospital-based Norwegian series.

Authors:  H Wang; P W Jebsen; R Kåresen; S O Thoresen
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

7.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Authors:  B Fisher; J Dignam; N Wolmark; D L Wickerham; E R Fisher; E Mamounas; R Smith; M Begovic; N V Dimitrov; R G Margolese; C G Kardinal; M T Kavanah; L Fehrenbacher; R H Oishi
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

8.  Effects of individualized breast cancer risk counseling: a randomized trial.

Authors:  C Lerman; E Lustbader; B Rimer; M Daly; S Miller; C Sands; A Balshem
Journal:  J Natl Cancer Inst       Date:  1995-02-15       Impact factor: 13.506

9.  Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.

Authors:  Ann Partridge; Kristie Adloff; Emily Blood; E Claire Dees; Carolyn Kaelin; Mehra Golshan; Jennifer Ligibel; Janet S de Moor; Jane Weeks; Karen Emmons; Eric Winer
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

10.  Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ.

Authors:  Ann Partridge; Jeffrey P Winer; Mehra Golshan; Jennifer R Bellon; Emily Blood; E Claire Dees; Ebonie Sampson; Karen M Emmons; Eric Winer
Journal:  Clin Breast Cancer       Date:  2008-06       Impact factor: 3.225

View more
  12 in total

1.  Psychological morbidity in women diagnosed with ductal carcinoma in situ compared with women with early breast cancer receiving radiotherapy.

Authors:  William Pidduck; Bo Angela Wan; Liying Zhang; Eileen Rakovitch; Selina Chow; Stephanie Chan; Caitlin Yee; Leah Drost; Philomena Sousa; Donna Lewis; Henry Lam; Eric Leung; Edward Chow
Journal:  Support Care Cancer       Date:  2019-08-26       Impact factor: 3.603

2.  Partnership Status and Socioeconomic Factors in Relation to Health Behavior Changes after a Diagnosis of Ductal Carcinoma In Situ.

Authors:  Sherrie Khadanga; Susan G Lakoski; Vicki Hart; Brian L Sprague; Yi Ba; John M Hampton; Stephen T Higgins; Philip A Ades; Polly A Newcomb; Amy Trentham-Dietz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-06       Impact factor: 4.254

3.  Recurrence risk perception and quality of life following treatment of breast cancer.

Authors:  Sarah T Hawley; Nancy K Janz; Kent A Griffith; Reshma Jagsi; Christopher R Friese; Allison W Kurian; Ann S Hamilton; Kevin C Ward; Monica Morrow; Lauren P Wallner; Steven J Katz
Journal:  Breast Cancer Res Treat       Date:  2016-12-21       Impact factor: 4.624

4.  What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment?

Authors:  Kamaria L Lee; Nancy K Janz; Brian J Zikmund-Fisher; Reshma Jagsi; Lauren P Wallner; Allison W Kurian; Steven J Katz; Paul Abrahamse; Sarah T Hawley
Journal:  Med Decis Making       Date:  2017-08-17       Impact factor: 2.749

Review 5.  Interventions are needed to support patient-provider decision-making for DCIS: a scoping review.

Authors:  Claire Kim; Laurel Liang; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi
Journal:  Breast Cancer Res Treat       Date:  2017-12-23       Impact factor: 4.872

6.  Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

Authors:  Lotte E Elshof; Marjanka K Schmidt; Emiel J Th Rutgers; Flora E van Leeuwen; Jelle Wesseling; Michael Schaapveld
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

Review 7.  Ductal carcinoma in situ: to treat or not to treat, that is the question.

Authors:  Maartje van Seijen; Esther H Lips; Alastair M Thompson; Serena Nik-Zainal; Andrew Futreal; E Shelley Hwang; Ellen Verschuur; Joanna Lane; Jos Jonkers; Daniel W Rea; Jelle Wesseling
Journal:  Br J Cancer       Date:  2019-07-09       Impact factor: 7.640

Review 8.  Quality of DCIS information on the internet: a content analysis.

Authors:  Jayden Blackwood; Frances C Wright; Nicole J Look Hong; Anna R Gagliardi
Journal:  Breast Cancer Res Treat       Date:  2019-06-18       Impact factor: 4.872

9.  Ductal carcinoma in situ (DCIS): The importance of patient-reported outcomes (PRO).

Authors:  Laura S Dominici; Shoshana M Rosenberg
Journal:  Curr Breast Cancer Rep       Date:  2020-04-04

10.  Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ.

Authors:  Tae-Kyung Yoo; Sang Hyun Park; Kyung Do Han; Byung Joo Chae
Journal:  BMC Cancer       Date:  2021-06-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.